vs
Side-by-side financial comparison of Aardvark Therapeutics, Inc. (AARD) and PROTHENA CORP PUBLIC LTD CO (PRTA). Click either name above to swap in a different company.
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for inflammatory, metabolic, and orphan diseases. It advances G-protein coupled receptor-targeting pipeline candidates, serving patient populations primarily in North America and global markets via R&D partnerships.
Prothena Corporation plc is a late-stage clinical biotechnology firm focused on developing and commercializing innovative antibody therapies for neurodegenerative disorders, rare diseases and immune-related conditions. Its core pipeline targets unmet medical needs including amyloidosis, Parkinson's and Alzheimer's, serving key markets across North America, Europe and the Asia-Pacific.
AARD vs PRTA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $0 | $21.0K |
| Net Profit | $-17.6M | — |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | — | — |
| Revenue YoY | — | -99.0% |
| Net Profit YoY | — | 62.7% |
| EPS (diluted) | $-0.81 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $0 | $21.0K | ||
| Q3 25 | $0 | $2.4M | ||
| Q2 25 | $0 | $4.4M | ||
| Q1 25 | $0 | $2.8M | ||
| Q4 24 | — | $2.1M | ||
| Q3 24 | — | $970.0K | ||
| Q2 24 | — | $132.0M | ||
| Q1 24 | — | $50.0K |
| Q4 25 | $-17.6M | — | ||
| Q3 25 | $-16.3M | $-36.5M | ||
| Q2 25 | $-14.4M | $-125.8M | ||
| Q1 25 | $-9.3M | $-60.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-59.0M | ||
| Q2 24 | — | $66.9M | ||
| Q1 24 | — | $-72.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | -1666.3% | ||
| Q2 25 | — | -1914.4% | ||
| Q1 25 | — | -2319.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -6857.0% | ||
| Q2 24 | — | 44.2% | ||
| Q1 24 | — | -163056.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | -1513.1% | ||
| Q2 25 | — | -2845.4% | ||
| Q1 25 | — | -2128.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -6082.6% | ||
| Q2 24 | — | 50.7% | ||
| Q1 24 | — | -144478.0% |
| Q4 25 | $-0.81 | — | ||
| Q3 25 | $-0.75 | $-0.68 | ||
| Q2 25 | $-0.66 | $-2.34 | ||
| Q1 25 | $-0.71 | $-1.12 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-1.10 | ||
| Q2 24 | — | $1.22 | ||
| Q1 24 | — | $-1.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $110.0M | $307.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $106.6M | $280.5M |
| Total Assets | $117.2M | $326.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $110.0M | $307.5M | ||
| Q3 25 | $126.3M | $330.8M | ||
| Q2 25 | $141.8M | $371.4M | ||
| Q1 25 | $151.3M | $417.9M | ||
| Q4 24 | — | $471.4M | ||
| Q3 24 | — | $519.3M | ||
| Q2 24 | — | $564.1M | ||
| Q1 24 | — | $546.5M |
| Q4 25 | $106.6M | $280.5M | ||
| Q3 25 | $122.4M | $295.0M | ||
| Q2 25 | $136.9M | $324.3M | ||
| Q1 25 | $150.7M | $437.7M | ||
| Q4 24 | — | $486.9M | ||
| Q3 24 | — | $534.4M | ||
| Q2 24 | — | $581.9M | ||
| Q1 24 | — | $502.4M |
| Q4 25 | $117.2M | $326.8M | ||
| Q3 25 | $133.2M | $352.6M | ||
| Q2 25 | $147.5M | $399.1M | ||
| Q1 25 | $157.0M | $495.3M | ||
| Q4 24 | — | $547.1M | ||
| Q3 24 | — | $595.3M | ||
| Q2 24 | — | $645.6M | ||
| Q1 24 | — | $623.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-16.8M | $-163.6M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-16.8M | $-163.6M | ||
| Q3 25 | $-16.1M | $-40.6M | ||
| Q2 25 | $-9.8M | $-46.3M | ||
| Q1 25 | $-11.4M | $-53.4M | ||
| Q4 24 | — | $-150.1M | ||
| Q3 24 | — | $-45.2M | ||
| Q2 24 | — | $16.0M | ||
| Q1 24 | — | $-73.1M |
| Q4 25 | — | — | ||
| Q3 25 | $-16.1M | — | ||
| Q2 25 | $-9.9M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.24× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
